ABOUT THIS EVENT

Silence Therapeucs plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, rang the Nasdaq Opening Bell remotely from United Kingdom.

In celebration of its IPO, Rob Quinn, Chief Financial Officer, rang the Opening Bell alongside the Company’s team in a virtual bell ringing ceremony.